These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9561116)

  • 1. Improvement of renal function with selective thromboxane A2 synthetase inhibitor, DP-1904 in lupus nephritis.
    Yoshida T; Kameda H; Masashi A; Homma M; Ikeda Y
    Adv Exp Med Biol; 1997; 433():113-7. PubMed ID: 9561116
    [No Abstract]   [Full Text] [Related]  

  • 2. Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis.
    Yoshida T; Kameda H; Ichikawa Y; Tojo T; Homma M
    J Rheumatol; 1996 Oct; 23(10):1719-24. PubMed ID: 8895147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904.
    Yoshida T; Ichikawa Y; Tojo T; Homma M
    Lupus; 1996 Apr; 5(2):129-38. PubMed ID: 8743126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of DP-1904, a thromboxane A2 synthetase inhibitor, on crescentic nephritis in rats.
    Nagao T; Ito M; Nagamatsu T; Suzuki Y
    Eur J Pharmacol; 1994 Jul; 259(3):233-42. PubMed ID: 7982449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of DP-1904, a new thromboxane A2 synthetase inhibitor, on guinea pig experimental asthma.
    Takami M; Takata Y; Matsumoto K; Ono S; Tsukada W
    Ann N Y Acad Sci; 1991; 629():407-9. PubMed ID: 1952565
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of DP-1904, a thromboxane A2 synthase inhibitor, on passive Heymann nephritis in rats.
    Nagao T; Nagamatsu T; Suzuki Y
    Eur J Pharmacol; 1996 Nov; 316(1):73-80. PubMed ID: 8982653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A thromboxane A2 synthetase inhibitor retards hypertensive rat diabetic nephropathy.
    Masumura H; Kunitada S; Irie K; Ashida S; Abe Y
    Eur J Pharmacol; 1992 Jan; 210(2):163-72. PubMed ID: 1350991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome.
    Zipser RD; Kronborg I; Rector W; Reynolds T; Daskalopoulos G
    Gastroenterology; 1984 Dec; 87(6):1228-32. PubMed ID: 6593268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a thromboxane A2 synthetase inhibitor on ventricular fibrillation threshold during coronary artery occlusion and reperfusion.
    Toda I; Nozaki A; Kawakubo K; Murakawa Y; Inoue H; Yoshimoto N; Sugimoto T
    Jpn Heart J; 1990 Jan; 31(1):87-97. PubMed ID: 2335849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of DP-1904, a thromboxane A2 synthase inhibitor, administered from the autologous phase on crescentic-type anti-GBM nephritis in rats.
    Nagao T; Nagamatsu T; Suzuki Y
    Jpn J Pharmacol; 1995 Jun; 68(2):137-44. PubMed ID: 7563970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a sustained thromboxane synthase inhibition on exercise-induced changes in eicosanoid formation, catecholamine concentration, and platelet aggregation in humans.
    Ohnishi A; Ishizaki T; Echizen H; Yasuda K; Fujiwara H; Tanaka T
    Clin Pharmacol Ther; 1992 Apr; 51(4):454-64. PubMed ID: 1563215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A thromboxane A2 synthase inhibitor, DP-1904, prevents rat renal injury.
    Masumura H; Kunitada S; Irie K; Ashida S; Abe Y
    Eur J Pharmacol; 1991 Feb; 193(3):321-7. PubMed ID: 2055246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of selective inhibition of thromboxane synthesis on renal function in humans.
    Zipser RD
    Am J Physiol; 1985 Jun; 248(6 Pt 2):F753-6. PubMed ID: 3839111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The functional and structural changes of the glomerulus throughout the course of murine lupus nephritis.
    Kiberd BA
    J Am Soc Nephrol; 1992 Oct; 3(4):930-9. PubMed ID: 1450369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a thromboxane synthetase inhibitor, dazoxiben, during haemodialysis.
    Dodd NJ; Gordge MP; Weston MJ
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):67S-70S. PubMed ID: 6337605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary excretion of prostacyclin and thromboxane metabolites in threatened preterm labor: effect of indomethacin and nylidrin.
    Kurki T; Viinikka L; Ylikorkala O
    Am J Obstet Gynecol; 1992 Jan; 166(1 Pt 1):150-4. PubMed ID: 1733190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis.
    Zoja C; Benigni A; Noris M; Corna D; Casiraghi F; Pagnoncelli M; Rottoli D; Abbate M; Remuzzi G
    Kidney Int; 2001 Aug; 60(2):653-63. PubMed ID: 11473648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of acute cyclosporine A nephrotoxicity by a thromboxane synthetase inhibitor.
    Smeesters C; Chaland P; Giroux L; Moutquin JM; Etienne P; Douglas F; Corman J; St-Louis G; Daloze P
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):658-64. PubMed ID: 3164534
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects.
    Morio H; Hirai A; Terano T; Tamura Y; Yoshida S
    Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term thromboxane-synthase inhibition prolongs survival in murine lupus nephritis.
    Salvati P; Lamberti E; Ferrario R; Ferrario RG; Scampini G; Pugliese F; Barsotti P; Patrono C
    Kidney Int; 1995 Apr; 47(4):1168-75. PubMed ID: 7783415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.